PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVerteporfin
Visudyne(verteporfin)
Visudyne (verteporfin) is a small molecule pharmaceutical. Verteporfin was first approved as Visudyne on 2000-04-12. It is used to treat choroidal neovascularization in the USA. It has been approved in Europe to treat degenerative myopia and macular degeneration.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Visudyne
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Verteporfin
Tradename
Company
Number
Date
Products
VISUDYNEBausch Health CompaniesN-021119 RX2000-04-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
visudyneNew Drug Application2025-08-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
choroidal neovascularization—D020256—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA01: Verteporfin
HCPCS
Code
Description
J3396
Injection, verteporfin, 0.1 mg
Clinical
Clinical Trials
106 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30————22
Wet macular degenerationD057135EFO_0004683—————22
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVerteporfin
INNverteporfin
Description
(2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid is the 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid. It is a beta-substituted porphyrin, a carboxylic acid and a methyl ester. It is functionally related to a (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid. It is an enantiomer of a (2S,2(1)R)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid.
Classification
Small molecule
Drug classbenzoporphyrin derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC
Identifiers
PDB—
CAS-ID129497-78-5
RxCUI—
ChEMBL IDCHEMBL2218885
ChEBI ID—
PubChem CID5362420
DrugBankDB00460
UNII ID0X9PA28K43 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,144 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,071 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use